This study focuses on patients with aortic stenosis, a condition where the heart’s aortic valve narrows, making it harder for blood to flow from the heart to the rest of the body. These patients will undergo a procedure called transcatheter aortic valve implantation (TAVI), which involves replacing the narrowed valve. The study specifically looks at patients who have high levels of heart muscle scarring (fibrosis).
The research aims to determine if medications that fight tissue scarring can help reduce heart muscle scarring after the valve replacement procedure. The study will use two medications: spironolactone and dihydralazine. Some patients will receive spironolactone alone, some will receive both medications together, and others will receive standard care without these additional medications.
The study will last 12 months, during which patients will take their assigned medications daily. To measure the amount of heart muscle scarring, patients will undergo cardiac magnetic resonance imaging (CMR) before their valve replacement procedure and again one year later. This imaging test uses a special dye called gadolinium to show areas of scarring in the heart muscle.
Germany 
